Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
What's Moving Markets Today? -- WSJ

What's Moving Markets Today? -- WSJ

Dow JonesDow Jones2026/10/19 18:59

By Heather Gillers

Stocks are up with the Nasdaq composite rising around 1% after a rough week last week when the tech-heavy index clocked its biggest decline since June.

"Those names that were kind of getting sold off last week are all bouncing," said Michael Antonelli, a managing director at Baird. Here's what's moving markets today:

-- Tech stocks are driving the rebound with Amazon and Tesla among the biggest gainers.

-- The yield on the 10-year Treasury is up. Renewed confidence in markets is leading investors to conclude that more growth--and more Fed rate hikes--are ahead, Antonelli said.

-- Big earnings week ahead: SpaceX and Netflix report quarterly earnings tomorrow and Meta and Tesla report Wednesday. Investors will be looking at capital expenditures for reassurance that the tech spending boom is still going strong.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

October 19, 2026 14:59 ET (18:59 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

智通财经•2026/10/26 06:41
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential

Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.

智通财经•2026/10/26 06:37